Aldeyra Therapeutics
(NASDAQ) ALDX
Aldeyra Therapeutics Financials at a Glance
Market Cap
$110.39M
Revenue (TTM)
$0.00
Net Income (TTM)
-$27.37M
EPS (TTM)
-$0.46
P/E Ratio
-4.02
Dividend
$0.00
Beta (Volatility)
1.80 (High)
Dividend
$0.00
Beta (Volatility)
1.80 (High)
Price
$1.91
Volume
21,854
Open
$1.88
Price
$1.91
Volume
21,854
Open
$1.88
Previous Close
$1.83
Daily Range
$1.88 - $1.99
52-Week Range
$1.07 - $6.18
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.80 (High)
Price
$1.91
Volume
21,854
Open
$1.88
Previous Close
$1.83
Daily Range
$1.88 - $1.99
52-Week Range
$1.07 - $6.18
Estimated Earnings Date
Aug 6, 2026
ALDX News
ALDX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Aldeyra Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
7
CEO
Todd C. Brady, MD, PhD
Website
www.aldeyra.comHeadquarters
Lexington, MA 02421, US
ALDX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-52%
Return on Capital
-67%
Return on Assets
-41%
Earnings Yield
-24.88%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$110.39M
Shares Outstanding
60.32M
Volume
21.85K
Avg. Volume
2.12M
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$35.27M
EBITDA
-$31.69M
Operating Cash Flow
-$33.35M
Capital Expenditure
$0.00
Free Cash Flow
-$33.35M
Cash & ST Invst.
$70.04M
Total Debt
$15.53M
Aldeyra Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$66.60K
N/A
Gross Margin
0.00%
N/A
Market Cap
$110.39M
N/A
Market Cap/Employee
$12.27M
N/A
Employees
9
N/A
Net Income
-$3.45M
+65.2%
EBITDA
-$2.92M
+68.9%
Quarterly Fundamentals
Total Cash
$65.00M
-27.8%
Total Debt
$15.51M
-0.3%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$15.51M
+2937.6%
Return on Assets
-41.17%
N/A
Return on Invested Capital
-67.33%
N/A
Free Cash Flow
-$5.11M
+59.0%
Operating Cash Flow
-$5.11M
+59.0%